Novartis and Microsoft have inked a five-year deal to use artificial intelligence to design molecules, personalize medication dosing, and optimize the manufacturing of CAR-T cancer therapy, the two companies announced Tuesday.
The partnership, whose financial terms were not disclosed, marks the latest and one of the more high-profile signs of the inroads that tech is making into drug development. It promises benefits for both sides: Novartis will get Microsoft’s help in mining data in search of insights that could help it save and make money, while Microsoft will get a chance to refine its own software for use in the life sciences.
About the Author Reprints
